Skip to main content
Premium Trial:

Request an Annual Quote

DxS' TheraScreen Gets Canadian OK

NEW YORK (GenomeWeb News) – DxS has received a license from Canadian regulatory authorities to sell its TheraScreen: K-RAS Mutation Kit as a companion diagnostic for Amgen's colorectal cancer therapy panitumumab (Vectibix), the UK-based firm said today.

In addition, Health Canada licensed the assay for broader use as a diagnostic for other anti-EGFR therapies beyond Vectibix.

DxS said that approximately 60 percent of metastatic colorectal cancer patients have a non-mutated KRAS gene, and studies have shown that patients with this particular marker may respond to Vectibix therapy.

Under a previously signed deal, Roche Diagnostics will distribute and support sales of the TheraScreen: K-RAS Mutation Kit in Canada beginning next month.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.